Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANI Pharmaceuticals

67.52
-0.7700-1.13%
Post-market: 67.520.00000.00%18:30 EDT
Volume:698.16K
Turnover:46.74M
Market Cap:1.47B
PE:-147.97
High:68.40
Open:66.02
Low:65.13
Close:68.29
Loading ...

Does ANI (ANIP) Have the Potential to Rally 31.31% as Wall Street Analysts Expect?

Zacks
·
26 Nov 2024

Compelling Reasons to Hold on to Ensign Group Stock Now

Zacks
·
22 Nov 2024

ANI (ANIP) Upgraded to Buy: What Does It Mean for the Stock?

Zacks
·
21 Nov 2024

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Zacks
·
20 Nov 2024

AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe

Zacks
·
18 Nov 2024

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

Zacks
·
14 Nov 2024

ANI Pharmaceuticals Price Target Maintained With a $94.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Nov 2024

Truist Financial Remains a Hold on ANI Pharmaceuticals (ANIP)

TIPRANKS
·
11 Nov 2024

ANI Pharmaceuticals: Buy Rating Backed by Consistent Revenue Growth, Strategic Acquisitions, and Strong Market Position

TIPRANKS
·
11 Nov 2024

ANI Pharmaceuticals Inc : Guggenheim Raises Target Price to $84 From $83

THOMSON REUTERS
·
11 Nov 2024

ANI Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
10 Nov 2024

ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com
·
09 Nov 2024

ANI Pharmaceuticals’ Record Growth and Strategic Acquisition

TIPRANKS
·
09 Nov 2024

ANI Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
09 Nov 2024

Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics

Zacks
·
08 Nov 2024

Stock Track | ANI Pharmaceuticals Soars on Record Q3 Results, Raised Outlook

Stock Track
·
08 Nov 2024

ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates

Zacks
·
08 Nov 2024

ANI Pharmaceuticals' Q3 Adjusted Earnings, Net Revenue Rise; Fiscal 2024 Outlook Lifted

MT Newswires Live
·
08 Nov 2024

ANI Pharmaceuticals Expects 2024 Adjusted EPS Of $4.90-$5.05 Versus Prior Guidance Of $4.38-$4.82 Versus Consensus Of $4.72

Benzinga
·
08 Nov 2024

ANI Pharmaceuticals Expects 2024 Revenues Of $594M-$602M Versus Prior Guidance Of $540M-$560M Versus Consensus Of $590.315M

Benzinga
·
08 Nov 2024